BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 9592622)

  • 1. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of antiandrogen monotherapy in the treatment of prostate cancer.
    Anderson J
    BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiandrogens as monotherapy for prostate cancer.
    Schröder FH
    Eur Urol; 1998; 34 Suppl 3():12-7. PubMed ID: 9854190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH
    Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogen monotherapy in the management of advanced prostate cancer.
    Kaisary AV
    Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
    Kolvenbag GJ; Iversen P; Newling DW
    Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
    Boccon-Gibod L
    Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
    Sciarra A; Cardi A; Di Silverio F
    Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
    Soloway MS; Matzkin H
    Cancer; 1993 Feb; 71(3 Suppl):1083-8. PubMed ID: 8428332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
    Gillatt D
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiandrogenic drugs.
    McLeod DG
    Cancer; 1993 Feb; 71(3 Suppl):1046-9. PubMed ID: 8428326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bicalutamide in advanced prostate cancer. A review.
    Goa KL; Spencer CM
    Drugs Aging; 1998 May; 12(5):401-22. PubMed ID: 9606617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
    Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
    J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.